NNC0491-6075

Evidence outlook · lead readout

NCT05979428 · Healthy Volunteers, Dyslipidaemia

The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.

NCT05979428: Participants were randomly assigned to drug or placebo under quadruple-blind conditions across ascending-dose cohorts, a sound early-safety design, but the primary measure was the number of adverse events rather than a clinical or lipid outcome, and results have not yet been reported.